AIM · AIM ImmunoTech Inc. · Executive Compensation
$0.19
+0.01 (+5.56%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred losses from operations and operating cash outflows exceeded cash inflows from operating activities for the six months ended June 30, 2026. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 7, 2026
Market Cap
$5.58M
Shares
30.44M
Volume · Oct 5
1.13M
Avg daily vol (3M)
4.7M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Chemerow | Independent Director | Appointed | 2025-02-26 |
| David I. Chemerow | Board of Directors | Appointed | 2025-02-26 |
| Nancy Bryan | Board of Directors | Appointed | 2023-03-30 |